Navigation Links
HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services
Date:12/3/2008

COLORADO SPRINGS, Colo. and REYKJAVIK, Iceland, Dec. 3 /PRNewswire/ -- HemoGenix(R) and ORF Genetics announce the collaboration and implementation of biorisk-free, green-source growth factors and cytokines for use in all HALO(R) Assay Kits and HALO(R) Contract Research Services where the response of human blood-forming cells is detected.

ORF Genetics produces a large number of growth factors and cytokines using barley seed as the production host. Their Orfeus(TM) Expression System, comprised of a barley endosperm expression background, gf22 expression cassette, HEKLAgro(TM) cultivation technology, and the production of isogenic lines for seed banking, makes this the most efficient and "green" production of human growth factors and cytokines for R&D medical research, cellular therapy, regenerative medicine, cosmetics and biopharma. ORF Genetics products are free of contaminants for bacterial, viral and prion components; non- pyrogenic; endotoxin-free; and perfectly safe according to FDA guidelines.

Through close collaboration, HemoGenix(R) has tested the growth factors and cytokines produced by ORF Genetics and found them to produce similar, if not superior, potency for growth of human bone marrow, cord blood and peripheral blood cells using its HALO(R) ATP-based, bioluminescence proliferation/cytotoxicity assay platform. The growth factors and cytokines needed to stimulate and detect various blood-forming stem and progenitor cell populations will now be incorporated into the complete line of HALO(R) Assay Kits produced by HemoGenix(R). This is particularly important for the family of HALO(R) quality control and potency assays used to ensure "stem cell quality" and "stem cell potency" for release of stem cell products, particularly umbilical cord blood, prior to transplantation into patients.

HemoGenix(R) will also incorporate ORF Genetics growth factors and cytokines into its HALO(R) Hemotoxicity Assay Kits and for its Contract Research Services using the HALO(R) Platform.

Ivan Rich, PhD, Founder and CEO of HemoGenix(R), said that, "It has been a pleasure working with ORF. Their response and products have been exceptional. Incorporating these growth factors and cytokines in our HALO(R) Platform products is extremely important for our quality control and potency assays, because we can now use biorisk- and contaminant-free products that provide far greater clinical relevance for the results that are obtained with our kits and services."

Bjorn Orvar, PhD, Co-founder and CEO of ORF Genetics, said that, "ORF Genetics ISOkine(TM) growth factors produced in our Orfeus(TM) plant-based production system are not only a novel approach for producing growth factors, but also a much-needed option for endotoxin-free, and animal- and serum-free components, for cell culture and medical research. HemoGenix(R) is a global leader of developing kits and assays for high throughput and validated cell- based assays for the detection and prediction of hemotoxicity, and we are very pleased to collaborate with HemoGenix(R) for the incorporation of our ISOkine(TM) growth factors and cytokines in its HALO(R) Hemotoxicity Assay Kits and Contract Research Services using the HALO(R) platform."

About HemoGenix(R), Inc

HemoGenix(R) was the first company in the world to provide high throughput and predictive cell-based in vitro assays to detect human hemotoxicity (toxicity to the blood-forming system). The HALO(R) Platform and other proprietary assays (LUMENESC(TM) and LumiSTEM(TM)) for different cell systems share the same ATP-based, in vitro bioluminescence technology. This allows biological responses to virtually any agent to be directly compared with each other across cell systems from different species simultaneously. Since its founding in 2000, HemoGenix(R) has developed its own portfolio of patented assays for basic research, toxicity, safety and risk assessment for the biopharmaceutical and environmental arenas, and quality control and potency assays for stem cell transplantation processing laboratories. HemoGenix(R) produces and sells its assays directly or through its distributors worldwide. HemoGenix(R) is a privately owned company.

About ORF Genetics, hf.

ORF Genetics was the first company to introduce biorisk-free growth factors to global R&D. Headquartered in Reykjavik, Iceland, ORF Genetics, hf. is a privately owned biotech company that is committed to economically viable, green technology for the production of growth factors and hard to produce recombinant proteins. Utilizing its unique Orfeus(TM) plant-based expression system, the company is currently the only provider of such growth factors to serve the needs of the medical research, cell culture media, diagnostics and cosmetic markets. ORF was recently awarded the prestigious 2008 Icelandic Innovation Award by the Icelandic Center for Research and the Icelandic Trade Council. The annual award is given to a single Icelandic company that is pioneering research and development.

    CONTACT:
    Ivan N. Rich, PhD
    Founder and CEO
    719-264-6250
    ivannr@hemogenix.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE HemoGenix, Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO).
2. Decision Biomarkers Inc Announces Formation of Scientific Advisory Board
3. Enigma Diagnostics Announces the Opening of a United States Office
4. Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
5. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
6. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
7. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
8. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
9. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
10. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
11. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... SC (PRWEB) , ... April 26, 2017 , ... ... mind, has teamed up with NASA to showcase the future of deep space ... Launch System (SLS) rocket and Orion spacecraft and includes a guest appearance by ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... drive high-level conversations among healthcare industry stakeholders, the discussion surrounding the topic will ... place May 15-18, 2017 in Los Angeles, Calif. Hosted by the Workgroup for ...
(Date:4/25/2017)... April 25, 2017 Providence ... licensed its novel immune-modulating technology to an undisclosed global ... allergy. Tregitopes, pronounced T·rej·itopes, are a ... by EpiVax CEO Annie De Groot ... immunoglobulin G, an autoimmune disease therapy, Tregitopes are ...
(Date:4/24/2017)... YORK , April 24, 2017  Dante Labs announced ... at only EUR 850 (ca. $900). While American individuals have ... the first time Europeans can access WGS below EUR 1,000. ... are crucial to leveraging genetic information to make informed decisions ... ...
Breaking Biology Technology:
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
Breaking Biology News(10 mins):